394 results match your criteria patients cml-cp


Tyrosine Kinase Inhibitors and Beyond for Chronic Myeloid Leukemia in Children.

Paediatr Drugs 2021 Apr 26. Epub 2021 Apr 26.

Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Columbia University Medical Center, 161 Fort Washington Ave, New York, NY, 10032, USA.

Chronic myeloid leukemia (CML) is rare in children but presents a unique challenge as recent drug innovations have turned CML into a chronic disease with implications for treatment into adulthood. With the approval of newer-generation tyrosine kinase inhibitors (TKIs) in addition to imatinib, providers have more options for the treatment of chronic-phase CML (CML-CP) in children. The second-generation TKIs approved for use in children, nilotinib and dasatinib, have higher response rates than first-generation imatinib; however, overall survival rates appear to be the same. Read More

View Article and Full-Text PDF

[Clinical characteristics, treatment pattern, and outcomes in newly diagnosed patients with chronic myeloid leukemia in the chronic phase by age].

Zhonghua Xue Ye Xue Za Zhi 2021 Feb;42(2):101-108

Peking University People's Hospital, Peking} University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing} 100044, China.

To explore the clinical characteristics, treatment patterns, and outcomes in newly diagnosed patients with chronic myeloid leukemia in the chronic phase (CML-CP) by age. Clinical data of consecutive ≥14 years old newly diagnosed CML-CP patients were retrospectively analyzed. This study included 957 patients. Read More

View Article and Full-Text PDF
February 2021

miR-181d/RBP2/NF-κB p65 Feedback Regulation Promotes Chronic Myeloid Leukemia Blast Crisis.

Front Oncol 2021 25;11:654411. Epub 2021 Mar 25.

Department of Hematology, Qilu Hospital of Shandong University, Jinan, China.

Background: Chronic myeloid leukemia (CML) is a malignant clonal proliferative disease. Once it progresses into the phase of blast crisis (CML-BP), the curative effect is poor, and the fatality rate is extremely high. Therefore, it is urgent to explore the molecular mechanisms of blast crisis and identify new therapeutic targets. Read More

View Article and Full-Text PDF

Leukemic stem cells shall be searched in the bone marrow before "tyrosine kinase inhibitor-discontinuation" in chronic myeloid leukemia.

Int J Lab Hematol 2021 Apr 9. Epub 2021 Apr 9.

Department of Hematology, Hacettepe University School of Medicine, Ankara, Turkey.

Background: Leukemic stem cells (LSCs) of chronic myeloid leukemia (CML), persisting in the bone marrow (BM) niche, could be responsible for the relapses within the patients of whom the treatment-free remission (TFR) had been attempted. We assessed the presence of the CML LSCs in the peripheral blood (PB) and concurrently in the BM in the patients with chronic-phase CML (CP CML).

Patients And Methods: Thirty-eight patients with CP CML were included into the study. Read More

View Article and Full-Text PDF

[Therapeutic Effect of Imatinib Made in Real World to Newly Diagnosed Chronic Myeloid Leukemia].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Apr;29(2):456-461

Department of Hematology, The First Affiliated Hospital of Gannan Medical University, Ganzhou 341000,Jiangxi Province, China,E-mail:

Objective: To evaluate the clinical efficacy and safety of domestic imatinib (made in China) in patients with newly diagnosed chronic myeloid leukemia chronic phase(CML-CP).

Methods: Fifty-seven newly diagnosed CML-CP patients who did not receive any other anti-CML treatment were treated by domestic imatinib 400 mg once a day. The hematological, cytogenetic and molecular reactions and safety were observed and evaluated after 3, 6 and 12 months of treatment. Read More

View Article and Full-Text PDF

Efficacy of allogeneic hematopoietic cell transplantation in patients with chronic phase CML resistant or intolerant to tyrosine kinase inhibitors.

Hematol Oncol Stem Cell Ther 2021 Mar 11. Epub 2021 Mar 11.

Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapies Program, Mayo Clinic Florida, Jacksonville, FL, USA. Electronic address:

Approximately 15-20% of chronic myeloid leukemia (CML) patients fail tyrosine kinase inhibitor (TKI) therapy secondary to resistance or intolerance. In the pre-TKI era, front-line allogeneic hematopoietic cell transplantation (allo-HCT) represented the standard approach for patients with chronic phase-CML (CP-CML) who were deemed fit to tolerate the procedure and had a human leukocyte antigen compatible donor available. Currently, CP-CML patients are eligible for allo-HCT only if they fail more than one TKI and/or are intolerant to the drug. Read More

View Article and Full-Text PDF

Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry.

Br J Haematol 2021 Mar 30. Epub 2021 Mar 30.

Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.

Clinical trials show that tyrosine kinase inhibitor (TKI) treatment can be discontinued in selected patients with chronic myeloid leukaemia (CML). Although updated CML guidelines support such procedure in clinical routine, data on TKI stopping outside clinical trials are limited. In this retrospective study utilising the Swedish CML registry, we examined TKI discontinuation in a population-based setting. Read More

View Article and Full-Text PDF

Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions.

Blood Rev 2021 Mar 16:100825. Epub 2021 Mar 16.

Division of Hematology & Hematologic Malignancies, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a reciprocal translocation [t(9;22)(q34;q11.2)] that leads to the fusion of ABL1 gene sequences (9q34) downstream of BCR gene sequences (22q11) and is cytogenetically visible as Philadelphia chromosome (Ph). The resulting BCR/ABL1 chimeric protein is a constitutively active tyrosine kinase that activates multiple signaling pathways, which collectively lead to malignant transformation. Read More

View Article and Full-Text PDF

Higher red blood cell distribution width at diagnose is a simple negative prognostic factor in chronic phase-chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: A retrospective study.

Medicine (Baltimore) 2021 Mar;100(10):e24003

The First Hospital of Lanzhou University, Lanzhou, Gansu, China.

Abstract: The aim of this study was to evaluate the ability of the red blood cell distribution width (RDW) to predict prognosis and treatment response in chronic myeloid leukemia (CML)-chronic phase (CP) patients treated with tyrosine kinase inhibitor (TKIs).We retrospectively enrolled 93 newly diagnosed CML-CP patients treated with TKIs from 2009 to 2018 at the First Hospital of Lanzhou University. Patients were divided into 2 groups using an RDW of 18. Read More

View Article and Full-Text PDF

A Pilot Study on Probing of Imatinib Induced Platelet Dysfunction in Patients with Chronic Myeloid Leukemia-Chronic Phase and Absence of Associated Bleeding Manifestation: Trying to Solve an Enigma.

Indian J Hematol Blood Transfus 2021 Jan 13;37(1):162-166. Epub 2020 Nov 13.

Department of Biotechnology, Maulana Abul Kalam Azad University of Technology, Kolkata, West Bengal 741249 India.

Imatinib, the first Tyrosine Kinase Inhibitor (TKI) used for the treatment of chronic myeloid leukaemia (CML) has revolutionized the management by inhibiting BCR-ABL tyrosine kinase. According to earlier reports there are concerns regarding the adverse effect of imatinib on haemostasis by causing platelet dysfunction. Here we studied platelet function using platelet aggregometry, in 19 CML chronic phase (CML-CP) patients on imatinib therapy, in complete haematologic response (CHR). Read More

View Article and Full-Text PDF
January 2021

Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial.

Leukemia 2021 May 11;35(5):1344-1355. Epub 2021 Mar 11.

University of Turin, Orbassano, Italy.

The ENESTfreedom trial assessed the feasibility of treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase (CML-CP) following frontline nilotinib treatment. Results for long-term outcomes after a 5-year follow-up are presented herein. Patients who had received ≥2 years of frontline nilotinib therapy and achieved MR underwent a 1-year nilotinib treatment consolidation phase before attempting TFR. Read More

View Article and Full-Text PDF

Treatment-free remission and immunity in chronic myeloid leukemia.

Authors:
Hiroshi Ureshino

Int J Hematol 2021 May 2;113(5):642-647. Epub 2021 Mar 2.

Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.

Chronic myeloid leukemia (CML) is caused by the reciprocal translocation t(9;22)(q34;q11), resulting in the BCR-ABL1 fusion gene. BCR-ABL1 tyrosine kinase inhibitors (TKIs) improve overall survival in patients with chronic phase CML (CML-CP). Approximately half of the patients who achieve a durable deep molecular response can achieve sustained treatment-free remission (TFR) after TKI discontinuation; thus TFR is now a therapeutic goal for most patients with CML-CP. Read More

View Article and Full-Text PDF

Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates.

Leuk Lymphoma 2021 Mar 1:1-14. Epub 2021 Mar 1.

Georgia Cancer Center at Augusta University, Augusta, GA, USA.

A physician survey (July 2019-August 2019) and a retrospective patient medical chart review (November 2019-December 2019) were conducted to assess TKI therapy discontinuation practice in patients with Ph + CML-CP in the US after the publication of practice guidelines updated with recommendations for TKI discontinuation. After guideline updates, 90% of physicians from the survey reported attempting TKI discontinuation and 24% of their patients discontinued TKI after achieving an adequate response. Although TKI therapy discontinuation practice is increasing, particularly in community-based practice, a little more than half of physicians were aware of these updated guidelines resulting in TKI discontinuation attempted under suboptimal conditions, mainly limited to first-line TKI therapy, with more than half of physicians access to at least MR4. Read More

View Article and Full-Text PDF

miRNome profiling of LSC-enriched CD34CD38CD26 fraction in Ph CML-CP samples from Argentinean patients: a potential new pharmacogenomic tool.

Front Pharmacol 2020 11;11:612573. Epub 2021 Jan 11.

Centro de Investigaciones Oncológicas-Fundación Cáncer, Ciudad Autónoma de Buenos Aires, Argentina.

Chronic myeloid leukemia (CML) is a myeloid stem cell neoplasm characterized by an expansion of myeloid progenitor cells and the presence of BCR-ABL1 oncoprotein. Since the introduction of specific BCR-ABL1 tyrosine kinase inhibitors (TKI), overall survival has improved significantly. However, under long-term therapy patients may have residual disease that originates from TKI-resistant leukemic stem cells (LSC). Read More

View Article and Full-Text PDF
January 2021

Prognostic effect of comorbidities in patients with chronic myeloid leukemia treated with a tyrosine kinase inhibitor.

Cancer Sci 2020 Oct 12;111(10):3714-3725. Epub 2020 Aug 12.

Department of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osaka-Sayama, Japan.

Comorbidities at diagnosis among patients with chronic myeloid leukemia in chronic phase (CML-CP) may affect their overall survival (OS) rate even in the tyrosine kinase inhibitor (TKI) era. However, the prognostic impact of comorbidities in patients with CML-CP treated with a second-generation TKI (2GTKI) has not been elucidated. We evaluated the effect of comorbidities on survival using the Charlson Comorbidity Index (CCI) in patients with CML-CP treated with imatinib or a 2GTKI (nilotinib and dasatinib). Read More

View Article and Full-Text PDF
October 2020

The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes.

Am J Hematol 2021 02 3;96(2):241-250. Epub 2020 Dec 3.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Extreme gradient boosting methods outperform conventional machine-learning models. Here, we have developed the LEukemia Artificial intelligence Program (LEAP) with the extreme gradient boosting decision tree method for the optimal treatment recommendation of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia in chronic phase (CML-CP). A cohort of CML-CP patients was randomly divided into training/validation (N = 504) and test cohorts (N = 126). Read More

View Article and Full-Text PDF
February 2021

Polymorphisms Are Associated with Treatment-Free Remission Following Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.

Mol Cancer Ther 2021 01 20;20(1):142-149. Epub 2020 Oct 20.

Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Saga University, Saga, Japan.

Treatment-free remission (TFR) is one of the therapeutic goals for patients with chronic phase chronic myeloid leukemia (CML-CP). Although previous reports indicated that antitumor immunity contributes to TFR, its determinants are still unclear. We previously reported that allelic polymorphisms of killer immunoglobulin-like receptors () and human leukocyte antigens () are associated with achievement of deep molecular response (DMR) in patients with CML-CP. Read More

View Article and Full-Text PDF
January 2021

[Disability Rating in Children and Adolescents with Chronic Myeloid Leukemia].

Klin Padiatr 2020 Oct 15. Epub 2020 Oct 15.

Department of Pediatric Hematology and Oncology, Clinic for Children and Adolescents, University of Erlangen Nuremberg, Erlangen.

Background: CML comprises only 2-3% of all diagnosed pediatric leukemias. Mostly diagnosed in chronic phase (CML-CP), the disease progresses without treatment to accelerated phase (CML-AP) and finally to life-limiting blastic phase (CML-BP). Contrasting the therapy of other leukemia types, CML-CP is not treated by intense chemotherapy but with oral drugs -termed tyrosine kinase inhibitors (TKI)- for an unlimited duration. Read More

View Article and Full-Text PDF
October 2020

The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis.

Haematologica 2020 Sep 14;Online ahead of print. Epub 2020 Sep 14.

Georgia Cancer Center at Augusta University (research performed while at MD Anderson Cancer Center).

Approximately 20-50% patients with chronic phase chronic myeloid leukemia (CML-CP) treated with tyrosine kinase inhibitors (TKIs) or with myelofibrosis (MF) treated with ruxolitinib develop grade ≥3 thrombocytopenia needing treatment interruptions and dose reductions. We conducted a non-randomized, phase II, single-arm study to determine the efficacy of eltrombopag for patients with CML or MF with persistent thrombocytopenia while on TKI or ruxolitinib. Eltrombopag was initiated at 50 mg/day, with dose escalation up to 300 mg daily allowed every 2 weeks. Read More

View Article and Full-Text PDF
September 2020

The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort.

Cancer Med 2020 12 10;9(23):8931-8939. Epub 2020 Oct 10.

Department of Hematology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan.

The European Treatment and Outcome Study (EUTOS) long-term survival (ELTS) score predicts disease-specific death in patients with chronic myeloid leukemia (CML) being treated with imatinib during the chronic phase (CP) of the disease. However, it is unclear whether the ELTS score predicts CML-related events or treatment responses. This study evaluated the predictive value of the ELTS score regarding prognosis and treatment response in patients with CML-CP. Read More

View Article and Full-Text PDF
December 2020

Sudden blast phase in pediatric chronic myeloid leukemia-chronic phase with abnormal lymphoid blasts detected by flow cytometry at diagnosis: Can it be considered a warning sign?

Cytometry B Clin Cytom 2020 Oct 8. Epub 2020 Oct 8.

Department of Medical Oncology, Tata Memorial Center, Mumbai, Maharashtra, India.

Background: Inconclusive knowledge persists regarding the course of chronic myeloid leukemia-chronic phase (CML-CP) patients with detectable abnormal blasts by flow-cytometry at diagnosis. The 2016 WHO classification is not specific regarding sub-classification of CML with <10% abnormal B-lymphoid blasts (ABLB), and suggests these patients often show rapid progression. We report the clinical course of pediatric CML-CP patients who had detectable abnormal blasts by flow-cytometry at baseline. Read More

View Article and Full-Text PDF
October 2020

Efficacy and safety profile of generic imatinib in patients with newly diagnosed chronic myeloid leukemia-chronic phase: sharing experience of a hemato-oncology center from eastern India.

Ann Hematol 2021 Jan 6;100(1):85-96. Epub 2020 Oct 6.

Department of Hematology, NRS Medical College, 138, AJC Bose Road, Kolkata, 700014, India.

In India, CML is the commonest adult leukemia. Imatinib is the gold standard for frontline treatment of newly diagnosed CML-CP patients. The present study was conducted to assess the efficacy and safety of generic imatinib in newly diagnosed CML-CP patients. Read More

View Article and Full-Text PDF
January 2021

Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study.

Clin Cancer Res 2021 Jan 14;27(1):70-77. Epub 2020 Sep 14.

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, P.R. China.

Purpose: Flumatinib has been shown to be a more potent inhibitor of BCR-ABL1 tyrosine kinase than imatinib. We evaluated the efficacy and safety of flumatinib versus imatinib, for first-line treatment of chronic phase Philadelphia chromosome-positive chronic myeloid leukemia (CML-CP).

Patients And Methods: In this study, 394 patients were randomized 1:1 to flumatinib 600 mg once daily ( = 196) or imatinib 400 mg once daily ( = 198) groups. Read More

View Article and Full-Text PDF
January 2021

Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo CP-CML Patients.

Cancers (Basel) 2020 Sep 4;12(9). Epub 2020 Sep 4.

Service d'Hématologie, Institut Bergonié, 33076 Bordeaux, France.

Tyrosine Kinase Inhibitors (TKIs) discontinuation in patients who had achieved a deep molecular response (DMR) offer now the opportunity of prolonged treatment-free remission (TFR). Aims of this study were to evaluate the proportion of de novo chronic-phase chronic myeloid leukemia (CP-CML) patients who achieved a sustained DMR and to identify predictive factors of DMR and molecular recurrence-free survival (MRFS) after TKI discontinuation. Over a period of 10 years, 398 CP-CML patients treated with first-line TKIs were included. Read More

View Article and Full-Text PDF
September 2020

[Curative Efficacy of First Generation TKI in the Treatment of CML-CP Combined with vPh and Analysis of Its Genetic Characteristics].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2020 Aug;28(4):1162-1166

Department of Hematology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, Yunnan Province, China,E-mail:

Objective: To investigate the curative efficacy of first generation TKI in the treatment of CML-CP combined with vPh and genetic characteristics.

Methods: 60 patients with CML-CP combined with vPh from January 2010 to May 2017 in the First Affiliated Hospital of Kunming Medical University were chosen as CML-CP-vPh group, and 107 patients with CML-CP combined with typical Ph chromosome at the same time were chosen as control group. The patients in two groups were treated with imatinib; The curative efficacy, karyotype and FISH signal type were compared between 2 groups, and the factors influencing long-term survival of patients were analyzed by Cox risk model. Read More

View Article and Full-Text PDF

Surrogate Markers for Treatment-Free Remission in Patients With Chronic Myeloid Leukemia.

Clin Lymphoma Myeloma Leuk 2020 Dec 16;20(12):785-790. Epub 2020 Jul 16.

Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan; Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga, Japan.

BCR-ABL1 tyrosine kinase inhibitors (TKIs) improve long-term survival of patients with chronic-phase (CP) chronic myeloid leukemia (CML). Recently, the treatment goal for patients with CML-CP became safe discontinuation of TKIs. Several clinical trials have shown that approximately half of patients who experience a durable deep molecular response during TKI treatment maintain molecular remission after discontinuation of TKIs. Read More

View Article and Full-Text PDF
December 2020

Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia.

Oncol Ther 2019 Dec 8;7(2):95-100. Epub 2019 Aug 8.

Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.

The management of chronic myeloid leukemia (CML) has been revolutionized by the discovery of tyrosine kinase inhibitors (TKIs) against BCR-ABL1 oncogenic fusion protein. Imatinib, the first BCR-ABL1 TKI, was introduced into clinical practice in the early 2000s. In the following years, the so-called second-generation TKIs (2GTKIs)-dasatinib, nilotinib, and bosutinib were approved, initially for patients resistant to imatinib, and subsequently for front-line treatment. Read More

View Article and Full-Text PDF
December 2019

BCR-ABL Gene Transcript Types of Patients with Chronic Myelogenous Leukemia in Yogyakarta, Indonesia.

Asian Pac J Cancer Prev 2020 Jun 1;21(6):1545-1550. Epub 2020 Jun 1.

Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/ Dr Sardjito General Hospital, Yogyakarta, Indonesia.

The aim of this study was analyzing the BCR-ABL transcript types of patients with chronic myeloid leukemia (CML) in Dr Sardjito General Hospital, Yogyakarta, Indonesia. This study is very relevant because the data concerning BCR-ABL gene transcript types is very limited in Indonesia. Furthermore, it is important for patient's management, particularly in defining the tyrosine kinase inhibitors (TKIs) therapy and monitoring after therapy. Read More

View Article and Full-Text PDF

A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting : R-EFECT study.

Wien Klin Wochenschr 2020 Aug 12;132(15-16):415-422. Epub 2020 Jun 12.

Department of Internal Medicine I, Division of Hematology & Hemostaseology and Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.

Background: Several clinical trials in chronic phase (CP) chronic myeloid leukemia (CML) showed that early response to tyrosine kinase inhibitor (TKI) treatment results in an improved long-term survival and progression-free survival. This study assessed whether patients achieving early treatment response (ETR; partial cytogenetic response or BCR-ABL1 mRNA ≤10% at 3 months) in daily practice also have a long-term survival benefit.

Methods: The Retrospective Evaluation of Early response in CML for long-term Treatment outcome (R-EFECT), a multicenter, retrospective chart review, documented patients with newly diagnosed CML-CP starting first-line TKI therapy in routine clinical practice. Read More

View Article and Full-Text PDF

Impact of anemia on the outcomes of chronic phase chronic myeloid leukemia in TKI era.

Hematology 2020 Dec;25(1):181-185

Department of Hematology, The Huaian Clinical College of Xuzhou Medical University, Huai'an, People's Republic of China.

It is common of chronic phase chronic myeloid leukemia (CML-CP) patients coexisting anemia at diagnosis, but the role of anemia on the prognosis is not clear. This study aims to explore impact of anemia on outcomes of CML-CP patients in TKI era. In the retrospective study, 258 newly diagnosed CML patients treated with TKIs were enrolled. Read More

View Article and Full-Text PDF
December 2020